Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The U.S. Food and Drug Administration ( FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

Inhaler: peak plasma concentrations of 49ng/mL reached within 15 minutes. Nasal spray: maximum venous concentrations of 2–12ng/mL reached in 4–15 minutes. Nasal Spray antagonized by nasal ...

But in future, those vaccines could come from inhalers or even pills ... "opens up for various other types of administration" from nasal sprays to pills, says its CEO Göran Conradsson.

Iconovo, which develops inhalable drugs based on proprietary inhalers and dry powder formulations, reports that it and Lonza initiated a collaboration to develop spray-dried formulations of an ...